- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04863092
Intervention to Educate and Improve Underrepresented Populations' Participation in Clinical Trials
Study Overview
Detailed Description
Clinical Trial Education Intervention: The educational intervention will be delivered to approximately 200 participants by the Community Health Educators (CHEs) who will conduct workshops to deliver content and educational materials to patients about the importance of participating in cancer clinical trials. The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group.
Additionally, the CHE and/or Patient Navigators (PNs) will set up pathways for communication with key personnel (i.e. nurse navigators, clinical research coordinators, investigators) from partnering hospitals and clinics to facilitate patient referrals and evaluation for eligibility for clinical trials. The CHE and/or PN will keep track of those individuals that are referred by the partner hospital and clinics to track if the PN referral resulted in enrollment and participation in a clinical trial. The CHE and/or PN will also record and report quarterly the number of: (a) persons referred to therapeutic/intervention CTs at the UCCC and partnering hospitals; (b) referred persons screened for therapeutic/intervention CTs at the UCCC and partnering hospitals; (c)referred persons enrolled in therapeutic/ intervention CTs at the UCCC and partnering hospitals.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jose Barron
- Phone Number: 303-724-5439
- Email: jose.barron@cuanschutz.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Hospital
-
Principal Investigator:
- Evelinn Borrayo
-
Contact:
- Jose Barron
- Phone Number: 303-724-5439
- Email: jose.barron@cuanschutz.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision to sign and date the consent form.
- Stated willingness to comply with all study procedures and be available for the duration of the study.
- Be over 18 years old
- English and/or Spanish Speaking
Exclusion Criteria:
- Individuals who do not meet eligibility criteria, including individuals who do not speak English or Spanish [at the discretion of the CHE or PN upon recruitment];
- Decisionally-challenged adults with cognitive or personality impairment or due to intoxication (alcohol or drugs) that might interfere with their ability to consent or participate in the study [at the discretion of the CHE or PN upon recruitment];
- Individuals from vulnerable populations (e.g., inmates, homeless, pregnant women, and those with auditory impairment [at the discretion of the CHE or PN upon recruitment].
- Individuals under the age of 18 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Underrepresented Population
A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty
|
The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions.
Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants.
Group sizes will be capped to 25 individuals per group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in knowledge and understanding of and intent to participate in Clinical Trials (CTs)
Time Frame: 36 months
|
Using questionnaires to measure the change in knowledge of and understanding and intent to participate in CTs
|
36 months
|
Number of patients referred, screened, and enrolled into cancer related therapeutic CTs
Time Frame: 36 months
|
Monitoring the number of referrals to and enrollment in CTs will help determine effectiveness of educational materials.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in number of underrepresented patients participating in cancer related therapeutic CTs
Time Frame: 36 months
|
In collaboration with the Cancer Clinical Trials Office (CCTO), the investigators will obtain quarterly demographic data for all participants across all clinical trials within the system and affiliate hospitals
|
36 months
|
Identify relationships between sociodemographic variables and the attitudes towards CTs
Time Frame: 36 months
|
For future studies, this can help provide insight as to what sociodemographic variables to target to increase CTs enrollment in the catchment area
|
36 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PN-referred persons screened for cancer related therapeutic CTS;
Time Frame: 36 months
|
The number of patients who interact with the site and connect with the PN for other services.
|
36 months
|
PN-referred persons enrolled in related therapeutic CTS;
Time Frame: 36 months
|
The number of patients who interact with the site and connect with the PN for other services.
|
36 months
|
connected to care services such as health insurance, treatment assistance programs
Time Frame: 36 months
|
The number of patients who interact with the site and connect with the PN for other services.
|
36 months
|
facilitate other services such as language translation, appointment scheduling, transportation, and childcare.
Time Frame: 36 months
|
The number of patients who interact with the site and connect with the PN for other services.
|
36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Evelinn Borrayo, MD, University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 20-0590.cc
- P30CA046934 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Educational Intervention
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBacterial Infection | Clostridium DifficileUnited States
-
McGill University Health Centre/Research Institute...University of Manitoba; Sunnybrook Health Sciences Centre; University of Alberta and other collaboratorsCompletedPeptic Ulcer Hemorrhage
-
Universidad de GranadaNot yet recruitingAsthma | Allergy
-
Roswell Park Cancer InstituteCompletedCervical Cancer | Breast CancerUnited States
-
US Department of Veterans AffairsDuke UniversityCompletedAccidental FallsUnited States
-
Gary MorrowNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
Azienda Unità Sanitaria Locale Reggio EmiliaCompletedMelanoma (Skin) | Educational ProblemsItaly
-
Goethe UniversityUnknownHealth Knowledge, Attitudes, PracticeGermany
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | LymphedemaUnited States
-
Claudia AristizábalUniversidad Nacional de Colombia; Universidad de Santander; Fundación Universitaria...Enrolling by invitationBurnout, Psychological | CaregiversColombia